Gelatinase inhibitors and prodrugs

Patent metadata

Field	Value
Publication number	US-8937151-B2
Application number	US-201113582678-A
Country	US
Kind code	B2
Filing date	Mar 4, 2011
Priority date	Mar 4, 2010
Publication date	Jan 20, 2015
Grant date	Jan 20, 2015

Abstract

The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.

First claim

What is claimed is:

1. A compound of Formula A:

wherein X is O, NH or —S—NH—, and R 1 is:

or R 3 ;
wherein
L is O, NH, —OCH 2 O—, or —C(═O)O—CH 2 O—;
each Y is independently —NH 2 , —CO 2 H, —P(═O)(OH) 2 , —OP(═O)(OH) 2 , Het, or a guanidine moiety;
Het…

Assignees

• Chang Mayland
• Mobashery Shahriar
• Lee Mijoon
• Univ Notre Dame Du Lac

Inventors

• Chang Mayland
• Mobashery Shahriar
• Lee Mijoon

Classifications

• A61P9/10

  Human Necessities · mapped topic

• A61P7/04

  Human Necessities · mapped topic

• A61P7/02

  Human Necessities · mapped topic

• A61P7/10

  Human Necessities · mapped topic

• A61P7/00

  Human Necessities · mapped topic